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The arrival of biosimilar monoclonal antibodies in oncology:
clinical studies for trastuzumab biosimilars
Liese Barbier 1, Paul Declerck1, Steven Simoens 1, Patrick Neven2, Arnold G. Vulto3 and Isabelle Huys1
The monoclonal antibody trastuzumab (Herceptin®), which targets the human epidermal growth factor receptor 2 (HER2), is
approved for the treatment of early breast and advanced breast and gastric cancer in which HER2 is overexpressed. Several
biosimilar versions of trastuzumab are expected to enter the European market over the course of 2018 and 2019. The biosimilar
development pathway consists of a comprehensive comparability exercise between the biosimilar candidate and the reference
product, primarily focussing on data from analytical studies. Clinical studies for biosimilar candidates follow a different design to
those for a new biological, as the aim is not to independently establish clinical beneﬁt, but to conﬁrm biosimilarity between the two
agents. The different trastuzumab biosimilar candidates have followed diverse pathways in their clinical development, with
differences in clinical trial design (equivalence or non-inferiority design), patient population (those with metastatic or early breast
cancer) and endpoint (overall response rate or pathological complete response). These differences in approach in phase 3 testing
must be viewed in the totality of evidence demonstrating biosimilarity. Adequate information on the biosimilar approval pathway,
the nature of the biosimilarity exercise and how the clinical development of a biosimilar is tailored to meet the licensing
requirements can help informed decision making in clinical practice.
British Journal of Cancer (2019) 121:199–210; https://doi.org/10.1038/s41416-019-0480-z
BACKGROUND
Biological medicines, and anticancer biological medicines in
particular,1 represent a growing ﬁnancial burden on healthcare
budgets. The loss of exclusivity rights on original biological
medicines has allowed biosimilar medicines to enter the market.
Biosimilars offer cost-effective treatment options that can help
contain the rising healthcare expenditure. The European Medi-
cines Agency (EMA) deﬁnes a biosimilar as ‘a biological medicinal
product that contains a version of the active substance of an
already authorised original biological medicinal product in the
European Economic Area’.2 Owing to the intrinsic variability that is
inherent to all biological medicines, and the complex manufactur-
ing process of these products, a biosimilar cannot be considered
an identical copy of the originally approved biological product
(the reference product or originator).3,4 Minor differences can exist
between the biosimilar and the reference product, but it needs to
be demonstrated that these differences are not clinically
meaningful.2,3 ‘Similarity to the reference medicinal product in
terms of quality characteristics, biological activity, safety and
efﬁcacy based on a comprehensive comparability exercise needs
to be established’.2 Table 1 provides an overview of the difference
between biosimilars and copies of originally approved small-
molecule medicines, called generics.
Regulatory authorities such as the EMA and the United States
Food and Drug Administration (FDA) have developed a regulatory
approval pathway for biosimilars.2,3 Since the authorisation of the
ﬁrst biosimilar in 2006 in Europe, >40 biosimilars have received a
positive opinion from the EMA and been subsequently authorised
by the European Commission (EC).5 Since 2015, the FDA has
approved over 10 biosimilars.6 The number of approved
biosimilars will grow substantially in future years, accompanied
by an increasing loss of exclusivity of biological reference
products, especially in oncology.7,8 By providing more-affordable
treatment options and introducing price competition to the
market, biosimilar medicines can generate signiﬁcant savings. The
cumulative savings between 2016 and 2020 in the EU5 and the
USA are estimated to range between 49 and 98 billion Euros.7
Savings derived from biosimilar market entry can relieve
burdened healthcare budgets and open up budgetary room for
new treatment options. Furthermore, biosimilar entry can increase
patient access to biological therapies.7,9
Biosimilars have been integrated in cancer care for over a
decade, as the ﬁrst biosimilars of epoetin and ﬁlgrastim were
authorised by the EMA in 2007 and 2008, respectively.5 The number
of biosimilars available in oncology is likely to increase rapidly, with
the therapeutic focus shifting from supportive care for chemother-
apy to targeted, potentially life-prolonging or curative monoclonal
antibodies (mAbs). The ﬁrst mAb biosimilar versions in oncology, of
rituximab, were approved by the EMA in 2017 (Blitzima®, Ritemvia®,
Rituzena®, Truxima® by Celltrion Healthcare Hungary Kft and
Rixathon®, Riximyo® by Sandoz GmbH).5
The mAb trastuzumab (developed by Genentech, marketed by
Roche as Herceptin®) targets the human epidermal growth factor
receptor 2 (HER2), and is approved for the treatment of early
breast and advanced breast and gastric cancer in which HER2 is
overexpressed (HER2+).10 HER2+ breast cancer accounts for
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~15% and 20% of all breast cancers in the early and advanced
stage, respectively.11 Trastuzumab in combination with pertuzu-
mab and taxane chemotherapy is currently the standard ﬁrst-line
treatment for HER2+ metastatic breast cancer.12 Trastuzumab is
also approved for the treatment of HER2+ early breast cancer in
neoadjuvant or adjuvant settings.11 As the ﬁrst therapeutic mAb
targeted to HER2, trastuzumab has revolutionised the treatment of
HER2+ breast cancer. However, its high cost (~30,500 Euros for
12 months’ treatment in an adjuvant setting and ~41,500 Euros for
an average treatment period of 18.5 months in metastatic breast
cancer, based on Belgian list prices for a patient that weighs 67
kg13) puts pressure on healthcare budgets and can restrict patient
access in countries where limited or no health insurance coverage
is available.14 Herceptin® had global sales of 6.6 billion Euros (7.5
billion USD15 at a 1.14 USD to 1 Euro conversion rate) in 2017 and,
with the patent expiration of the intravenous reference product of
Herceptin® in the European Union (EU) in 2014 and the expected
patent expiration in the USA in 2019,8 several companies have
been pursuing the development of biosimilar versions of
trastuzumab. Five trastuzumab biosimilars have been approved
by the EC16–20 and are expected to enter the European market
over the course of 2018 and 2019. In the United States of America,
three trastuzumab biosimilars have so far been authorised21,22 and
are expected to enter the USA market in 2019.8
However, not all markets are ready to capture the potential
beneﬁts offered by biosimilars, as the uptake of biosimilars across
Europe is heterogeneous and limited in some countries.7,23 The
lack of knowledge and understanding among stakeholders about
the biosimilar approval pathway and the different weight of
clinical data in the development of biosimilars compared with that
of an originator have been identiﬁed as hurdles for the uptake of
biosimilars.24,25 As more biosimilars are approved and prescribed,
especially in the domain of cancer with the recent approvals of
therapeutic oncology biosimilars, it becomes increasingly impor-
tant that healthcare providers have a good understanding about
the biosimilar approval pathway and the role of clinical data in
this. To address this need, the aim of this manuscript is threefold:
ﬁrst, to provide an overview of the biosimilar development
pathway; second, to review the clinical trial parameters and
published clinical data that have been collected to conﬁrm
similarity between the reference product – in this case, we will
focus on trastuzumab – and its biosimilars in relation to the EMA
guidelines on (mAb) biosimilar development; and, third, to
provide information that can be useful in clinical decision making
for prescribers and other healthcare providers who will be using
trastuzumab biosimilars in clinical practice.
THE DEVELOPMENT OF BIOSIMILARS
The development of biosimilar versions of previously approved
biological products is based on a rigorous comparability exercise
between the biosimilar and the reference product. Different from
the marketing authorisation application of the reference product,
the goal of the biosimilarity exercise is not to independently
establish the clinical beneﬁts of the candidate, as this has already
been demonstrated for the reference product,26 but to demon-
strate a high degree of similarity to the reference product in terms
of quality characteristics, biological activity, efﬁcacy and safety,
and to exclude any clinically relevant differences that might exist
between the reference product and the biosimilar.2
Biosimilar development starts with a comprehensive physico-
chemical and biological characterisation, including a comparison
of quality attributes, followed by comparative nonclinical
studies.3,4 Further, clinical comparative testing is required to
ensure similar pharmacokinetics (PK) and to conﬁrm similar
efﬁcacy and safety to the reference product.3 Compared with
the approval pathway for a new biological, the biosimilarity
exercise places more emphasis on data from the extensive
physicochemical and biological characterisation of the candidate
and the comparative analytical testing with the reference product
and less on those from clinical trials.2,3,27 The nature and extent of
each step of the clinical development depends on the level of
evidence obtained in the previous steps of the comparability
exercise.2,3 The clinical package generally consists of a phase
1 study followed by at least one phase 3 study for one of the
approved indications of the reference product.3 In some cases,
conﬁrmatory PK and pharmacodynamic (PD) studies might be
sufﬁcient to demonstrate clinical biosimilarity.27 At the end of the
process, the biosimilar is evaluated on the overall body of
evidence for biosimilarity.3 Figure 1 provides a schematic overview
of the differences in approach between the development of a new
biological and a biosimilar.
The EMA has issued several guidance documents to assist
sponsors in the development of biosimilars,28–30 including a
product-speciﬁc guideline for biosimilar mAbs.26 The EMA applies
a case-by-case approach when guiding and evaluating the
comparability exercise of a biosimilar.26 In this article, we discuss
the clinical development of trastuzumab biosimilars in relation to
EMA guidelines; some minor differences exist with FDA guidelines,
but they are based on the same principle of establishing
biosimilarity to the reference product.3 As the goal of the
biosimilarity exercise is different to that of the development of a
new product, the design of the clinical studies for the evaluation
of biosimilars is also different to that for a new product.3 The
studies should primarily be sensitive enough in the choice of
design, population and primary endpoint such that any relevant
(clinically meaningful) differences between the reference product
and the biosimilar could be detected.2,26
EMA BIOSIMILAR (MAB) GUIDELINES ON PHASE 1 PK/PD
TESTING
The primary goal of PK studies in biosimilar development is to
show comparability in PK between the biosimilar candidate and
Table 1. The difference between biosimilars and generics
A generic is a copy of a an existing small-molecule-based therapeutic and its approval is based on the demonstration of bioequivalence with its
reference product by appropriate pharmacokinetic studies.2,27
A biosimilar is a biological medicinal product that is highly similar to an already licensed biological medicine, the reference product.2 Owing to the
intrinsic variability that is inherent to all biological medicines and the complex manufacturing of these medicines, it is impossible to produce identical
products. Minor differences can thus exist between the biosimilar and the reference product, however it needs to be demonstrated that these
differences are not clinically meaningful.3
The development of a biosimilar is based on the demonstration of biosimilarity via extensive head-to-head comparability studies to the reference
product.2
Generics and biosimilars both follow an abbreviated development pathway for regulatory approval compared with that of an original medicine,
however, the requirements are different. As a biosimilar cannot be an exact copy of the reference product, owing to the natural variability and
complex manufacturing process of biological medicines in general, the ‘generic’ development and approval approach is not appropriate for a
biosimilar.2,27
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the reference product. Unless the product carries speciﬁc safety
concerns, the EMA guideline on mAb biosimilar development and
the EMA guideline on investigation of bioequivalence recommend
performing PK testing in healthy volunteers,26,31 as they are less
likely to show variability in PK compared with patients, and thus
are a more sensitive and homogenous group in which to detect
potential clinically meaningful differences in PK characteristics
between the two products.26 It is also advisable to collect
supportive PK data in the clinical patient studies. A single-dose
study with a parallel group design is advised, owing to the long
half-life of mAbs and the potential impact of immunogenicity. In
addition to conventional PK parameters, including the area under
the curve (AUC) and Cmax, it is advisable to measure safety and
immunogenicity parameters in parallel, such as the presence of
antidrug antibodies.26
PK studies can, when available, be combined with PD
endpoints, which can add valuable information for the compar-
ability exercise, especially if the PD endpoints are sensitive enough
to detect small differences between the biosimilar and the
reference product, and if they can be measured with sufﬁcient
precision.26 PD testing can potentially also be considered as
pivotal evidence to establish clinical biosimilarity, provided that a
clear dose–response relationship can be shown and a PD marker
that is accepted as surrogate marker of a patient outcome is
available.26 If this is not the case, similar clinical efﬁcacy needs to
be demonstrated in a phase 3 comparative trial.26
EMA BIOSIMILAR (MAB) GUIDELINES ON PHASE 3 STUDIES
The primary objective of a phase 3 biosimilarity trial is to
demonstrate similar clinical efﬁcacy and safety between the
candidate and its reference product. To this end, the EMA advises
conducting an adequately powered, randomised, parallel group
comparative clinical trial, preferably double-blind, with an equiva-
lence study design, for at least one representative indication.26
To allow detection of potential differences between the
candidate biosimilar and the reference product, the EMA advises
conducting the phase 3 trial in the most sensitive and
homogenous patient population.26 Reducing patient-related
factors and disease-related factors (e.g., differences in disease
severity or different previous lines of treatment) to a minimum will
allow potential differences to be attributed to the product, rather
than to the patient or the disease.26
Progression-free survival (PFS) and overall survival (OS) are
conventional endpoints that are used to demonstrate efﬁcacy in
cancer indications. However, it might not be feasible to use these
as primary endpoints for phase 3 biosimilarity trials, as they
require a long follow-up period. Furthermore, they might not be
sensitive enough to demonstrate comparability, as they can be
inﬂuenced by non-product-related factors, such as tumour
burden, performance status and previous and or later lines of
treatment. Therefore, the use of a sensitive endpoint that
measures shorter-term activity is recommended, although, when
feasible, it is advisable to record PFS and OS in addition.26
As well as comparable efﬁcacy, comparable safety needs to be
demonstrated during phase 3 evaluation. Adverse events,
particularly those described for the reference product, and
immunogenicity, by measuring antidrug antibodies, should be
assessed.26
TRASTUZUMAB BIOSIMILARS IN CLINICAL DEVELOPMENT
Several trastuzumab biosimilar candidates have been developed,
with at least seven of them entering clinical development (Fig. 1).
Five developers, Samsung Bioepis (SB3), Celltrion (CT-P6), Mylan/
Biocon (MYL-1401O), Amgen/Allergan (ABP 980) and Pﬁzer
(PF-05280014) have submitted their candidate for marketing
authorisation to the EMA. In September 2017, the committee for
medicinal products for human use (CHMP) recommended the
granting of a marketing authorisation for Samsung Bioepis’
candidate, SB3 (Ontruzant®).32 Four other recommendations
for approval followed for Celltrion’s product (CT-P6, Herzuma®),
ABP 980 from Amgen/Allergan (Kanjinti®), Pﬁzer’s candidate
(PF-05280014, Trazimera®) and Mylan’s product (MYL-1401O,
Ogivri®).33–36 These products received a marketing authorisation
from the EC16–20 and are gradually entering the European market.
Mylan/Biocon, Celltrion, Amgen/Allergan, Samsung Bioepis and
Pﬁzer also submitted a Biologics License Application (BLA) for their
New medicine development Biosimilar development
Clinical trial(s) in the most
sensitive indication(s)
Molecule
characterisation
Physicochemical and
biological characterisation
Preclinical Preclinical
PK/PD PK/PD
Clinical trials per
indication
Biosimilar
(candidate)
BCD-022
ABP 980 Kanjinti® Amgen/Allergan
Biocad
CT-P6 Herzuma® Celltrion
Meiji Seika PharmaDMB-3111
MYL-14010 Ogivri®
PF-05280014 Trazimera®
Ontruzant®
Pfizer
SB3 Samsung Bioepis
Brand name Company
Mylan/Biocon
Phase 1 Phase 3 MAA
EMA
Status EMA Status EC
Positive opinion
Positive opinion
Positive opinion
Positive opinion
Positive opinion Approved
Approved
Approved
Approved
Approved
a
b
Fig. 1 Biosimilar development: an overview of the development pathway and the different trastuzumab biosimilar(s) (candidates) approved
or in clinical development. a New medicine versus biosimilar medicine development. Adapted from McCamish (2011) Mabs.93 b Key
trastuzumab biosimilar candidates approved or in clinical development (status December 2018). EC: European Commission, EMA: European
Medicines Agency, MAA: marketing authorisation application
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candidate to the FDA.15,37 In December 2017, the FDA announced
the approval of Ogivri® (MYL-1401O) as ﬁrst trastuzumab
biosimilar in the USA.21 Herzuma® (CT-P6), Ontruzant® (SB3) and
Trazimera® (PF-05280014) have been approved in December 2018,
January 2019 and March 2019, respectively.22
Some of these recently EC/FDA-approved trastuzumab biosimi-
lars or candidates are already on the market in other regions of
the world. For example, the candidate co-developed by Mylan and
Biocon was launched in India in 2013 (under the brand names
Hertraz® and CANMab®, respectively). Celltrion has marketed its
candidate as Herzuma® in South Korea since 2014 and Biocad’s
product has been marketed in Russia under the brand name
HERtiCAD® since 2016.15 As the regulatory approval process is less
stringent in countries such as Russia and India, these products
should not be considered as biosimilars before being assessed by
regulatory authorities such as the EMA and FDA.15
CLINICAL DATA FROM PHASE 1 TRASTUZUMAB BIOSIMILAR
TRIALS
All seven trastuzumab biosimilar candidates showed an equivalent
PK proﬁle to the reference product, as primary PK outcomes fell
within the pre-speciﬁed bioequivalence margin of 80–125%, with
a 90% Conﬁdence Interval (CI). Although EMA guidelines
recommend PK testing for mAbs in healthy volunteers, Celltrion
and Biocad performed PK testing in HER2+ patients with
metastatic breast cancer.38,39 Other developers, however, followed
the EMA guidelines and conducted PK testing for their candidate
in healthy volunteers.40–45 Table 2 provides an overview of the
trial parameters and phase 1 PK outcomes for the different
biosimilar candidates. The patient population size varied from 46
(BCD-022) to 174 (CT-P6) healthy volunteers or patients.
The reported safety results were overall comparable between
the respective biosimilar and the trastuzumab reference product.
An overview of phase 1 safety outcomes is shown in Table 3.
Amgen/Allergan reported a treatment-emergent adverse event
(TEAE) incidence of 84%, 75%, and 78% in subjects receiving their
candidate (ABP 980), USA-sourced trastuzumab and EU-sourced
trastuzumab, respectively.40,41 PF-05280014, Pﬁzer’s candidate,
showed a numerically higher incidence of pyrexia in the biosimilar
treatment arm, but the severity of this adverse event was reported
to be generally mild.44 Phase 1 comparative testing of SB3 showed
a numerical higher TEAE incidence for the EU-sourced trastuzu-
mab and the USA-sourced trastuzumab compared to SB3 (44.4%,
61.1%, and 36.1%, respectively).45 Events related to cardiac
function – patients treated with trastuzumab have a small to mod-
erately increased risk of cardiotoxicity – were reported for some of
the candidates. In addition, a phase 1 study for the candidate of
Amgen/Allergan (at that time referred to as FTMB, developed by
Synthon46) by Wisman et al. investigated the cardiotoxicity of ABP
980 in healthy volunteers and added a dose-escalation part while
monitoring the cardiac function.47 During the dose-escalation
period, no safety concerns that would impede progression of the
study towards its bioequivalence phase were detected using
either the biosimilar or the reference product.
A lack of clinically validated PD markers for trastuzumab makes
it necessary to conﬁrm clinical comparability via a phase 3
trial.26,48
PHASE 3 EFFICACY AND SAFETY TESTING FOR TRASTUZUMAB
BIOSIMILAR CANDIDATES
Six trastuzumab biosimilar candidates have been tested in phase 3
trials. Reported phase 3 data are in support of biosimilarity
between the candidates and the trastuzumab reference product.
For ﬁve candidates equivalence in efﬁcacy to trastuzumab was
considered to be established (for ABP 980, CT-P6, MYL-1401O, PF-
05280014 and SB3).49–56 For BCD-022, non-inferiority in efﬁcacy to
trastuzumab was demonstrated in metastatic breast cancer
patients.57 Differences in the selected patient population, primary
endpoints and trial design exist between the different candidates.
Table 4 shows the trial parameters and a summary of comparative
efﬁcacy results for the phase 3 trials. Candidate-speciﬁc phase 3
results are further discussed in the supplementary information of
this article. The reported safety data of phase 3 testing can be
viewed in Table 5.
A ﬁrst point of variation in the phase 3 clinical development of
the different trastuzumab biosimilar candidates is the selected
patient population. As trastuzumab is approved in the treatment
of patients with metastatic breast cancer, early breast cancer and
metastatic gastric cancer, the sponsor can decide between
different patient settings in which to test its candidate. Without
specifying its preference for metastatic breast cancer or early
breast cancer, the EMA advises conducting phase 3 testing in the
most sensitive and homogeneous population.26 It could be argued
that patients with metastatic breast cancer potentially represent a
less homogeneous, and thus less sensitive, group owing to a
number of confounding factors, such as location of metastases,
comorbidities, disease severity and the number and type of prior
therapies.48,58–60 Unless adequately controlled for in the statistical
design of the study, this heterogeneity is likely to have an impact
on the validity of the trial’s conclusions.48 In this regard, early
breast cancer might represent a more sensitive and homogeneous
population, as patients with early breast cancer generally have
fewer confounding characteristics (little or no prior therapy and
generally a better performance status).48,58–60 Mylan/Biocon and
Biocad chose to conduct their phase 3 trial in patients with
metastatic breast cancer,57,61,62 whereas Samsung Bioepis and
Amgen/Allergan performed their phase 3 trial in early breast
cancer patients.54–56,63 Pﬁzer and Celltrion conducted two phase 3
trials, one for each patient setting.64–67 The phase 3 Pﬁzer trial in
early breast cancer was based on a PK primary endpoint.64
Celltrion’s phase 3 trial in metastatic breast cancer was not
submitted to EMA as part of the marketing authorisation
application. Table 4 provides an overview of phase 3 trial
parameters for the different candidates. The patient population
size varied from 126 (BCD-022) to 800 (SB3) patients.
A second point of variation in clinical testing is the choice of
clinical trial endpoint. According to the product-speciﬁc EMA
guideline of biosimilar mAbs, the clinical endpoint that is most
sensitive at detecting product-related differences should be
selected.26 A surrogate clinical endpoint that measures shorter-
term activity as the primary endpoint may be considered.26
Response rates such as overall response rate (ORR; the proportion
of patients in whom a complete response (CR) or partial response
(PR) was observed) and pathological complete response (pCR)
might be suitable for detecting meaningful differences in activity
between the candidate and its reference product, if any.26 In the
case of trastuzumab biosimilars, pCR could be deemed as the
more favourable endpoint, as it has been shown to correlate with
long-term survival in patients with early breast cancer.59,68 A
pooled analysis of 12 randomised controlled trials of neoadjuvant
therapy in early breast cancer with ~12,000 patients showed that
pCR was associated with a long-term survival outcome.69 In this
regard, pCR in early breast cancer (Amgen/Allergan, Celltrion,
Samsung Bioepis) might be a more desirable approach in
establishing clinical biosimilarity than ORR in metastatic breast
cancer (Biocon, Mylan, Pﬁzer).
The deﬁnition of the primary endpoint also differs across
studies. Of the three sponsors who chose to conduct their (main)
phase 3 trial in early breast cancer, two – Amgen/Allergan and
Celltrion – selected pCR in both breast tissue and axillary lymph
nodes (total pCR (tpCR));55,56,67 the third, Samsung Bioepis, chose
pCR in breast tissue alone (breast pCR (bpCR)) as the primary
endpoint.54 The tpCR could potentially be deemed as a more
convincing primary endpoint by the prescriber, as the eradication
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of tumour from both breast and lymph nodes has been shown to
have a stronger association with improved long-term survival
outcomes, than eradication from the breast alone.69,70
The selected endpoints for the evaluation of biosimilarity might
be less acceptable for oncologists, as they are different from the
conventional efﬁcacy endpoints that show patient beneﬁt.
However, the goal of the comparability exercise is to demonstrate
biosimilarity rather than patient beneﬁt, which has already been
demonstrated for the reference product. Therefore, it is important
to inform clinicians and other healthcare providers about the
rationale behind the biosimilar development pathway and its
stepwise approach.
The choice between an equivalence or a non-inferiority trial
design is a third point of variation. As the biosimilar concept is
based on demonstrating similarity of the biosimilar to its reference
product, the EMA advises an equivalence study design for phase 3
testing of mAb biosimilars.26 An equivalence trial is intended to
demonstrate that neither the candidate nor the comparator (the
reference product) is inferior or superior to the other, by showing
that any difference in response between the two is likely to lie
within a pre-speciﬁed range of clinically acceptable differences.71
Most of the companies have adhered to EMA guidance by
deciding on a two-sided equivalence test to demonstrate similar
clinical efﬁcacy and safety to trastuzumab.
In contrast, Biocad’s candidate (BCD-022) was tested in a non-
inferiority trial.57 A non-inferiority trial tends to require a smaller
sample size than equivalence testing, but only rules out inferiority,
not potential superiority, to the reference product.71 The clinical
trial of BCD-022 was performed in a relatively small patient cohort
of 126 patients with metastatic breast cancer with the non-
inferiority margin set at −20% with a 95% CI for risk difference in
ORR. The results showed that the lower limit of the 95% CI for risk
difference in ORR between the groups (−19.83%) did not exceed
the non-inferiority margin, demonstrating non-inferiority to
trastuzumab.57 BCD-022 was approved by the Ministry of Health
of the Russian Federation at the beginning of 2016, but has not
been submitted for approval in Europe or in the USA.15 Based on
the results of this study, it is unlikely that BCD-022 would be
granted marketing authorisation as a biosimilar by rigorous EMA
standards. Pﬁzer also performed a non-inferiority phase 3 trial (in a
neoadjuvant setting, Ctrough at steady state as the primary
endpoint with secondary efﬁcacy endpoints).64 However, Pﬁzer’s
pivotal phase 3 trial adhered to an equivalence design (in patients
with metastatic breast cancer, with ORR as the primary
endpoint).65
For SB3, the lower boundary of the 95% CI for risk difference in
bpCR (95% CI: 4.13, 17.26) fell within the predeﬁned equivalence
margin (−13%, +13%), while the upper boundary exceeded the
equivalence margin,54 ruling out non-inferiority but not potential
superiority. The boundaries of the 95% CI for the ratio of bpCR (95%
CI: 1.085, 1.460) fell within the predeﬁned equivalence margin
(0.785, 1.546), demonstrating equivalence.54 For ABP 980, based on
predeﬁned local review, the lower boundaries of the 90% CI for both
risk difference and risk ratio of pCR fell within the pre-speciﬁed
equivalence margins and the upper boundaries of the CI for both
exceeded the equivalence margins, thereby excluding non-
inferiority but not potential superiority.55,56 In sensitivity analyses
based on central independent review of tumour samples by blinded
pathologists, the risk difference and risk ratio of pCR fell within the
equivalence margins.55,56 These observations for SB3 and ABP 980
were deemed at least partially confounded by a small downward
shift in ADCC activity in the EU trastuzumab reference pro-
duct batches (as described in the literature72) that were used in
their phase 3 comparative trial, as stated in the European public
assessment report of both Ontruzant® (SB3) and Kajinti® (ABP
980).49,53 Both SB3 and ABP 980 have been approved as a biosimilar
of trastuzumab, as the overall body of evidence sufﬁciently
demonstrated biosimilarity compared to the reference product.49,53T
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EXTRAPOLATION OF INDICATIONS
A biosimilar candidate can be considered for approval for one or
more indications for which the reference product is approved,
without itself being subjected to clinical testing for all of these
indications. This regulatory concept is called extrapolation of
indications.26,73 The main rationale for extrapolation of data to
other indications is to avoid unnecessary clinical studies.74,75
Extrapolation is decided on a case-by-case basis, taking into
account the overall evidence gathered in the comparability
exercise of the candidate, including safety, efﬁcacy and immuno-
genicity data, in a key indication that is suitable to detect clinically
meaningful differences, and the scientiﬁc justiﬁcation for extra-
polating.26 The scientiﬁc justiﬁcation requires detailed knowledge
of the mechanism of action and the targets involved, the PK
proﬁle, immunogenicity and adverse events that might be
expected in the different indications.26,28,73 If the mechanism of
action is complex and involves multiple receptors or binding sites
that contribute differently to the different therapeutic indications,
additional data might be required to allow for extrapolation.75
Extrapolation is an established regulatory principle that is not
only applied in the context of biosimilars, but also for example
when a new formulation of a licensed product is developed.73,74
For instance, Roche has developed a subcutaneous formulation of
trastuzumab, which was clinically tested in the neoadjuvant
setting and was approved in Europe in 2013 for all indications
after extrapolating to the metastatic setting.73,76 Although the
concept of extrapolation is essential in the biosimilar development
pathway, the use of extrapolation of indication has raised
concerns among healthcare providers.24,73 In particular, if the
reference product is used across different therapeutic areas (e.g.,
autoimmune disease and oncology), different pathologies (e.g.,
breast cancer and gastric cancer) or different disease settings (e.g.,
ﬁrst-line and second-line), extrapolation can be perceived as
challenging. The ﬁrst biosimilar of rituximab, Truxima®, was
approved for all indications of rituximab, including indications in
oncology, after it was tested in a pivotal phase 3 trial in
rheumatoid arthritis patients, and supportive data were gathered
in patients with advanced follicular lymphoma (similarity in PK and
non-inferiority in efﬁcacy).77 For trastuzumab biosimilars, extra-
polation has already been granted by the EMA both from early
breast cancer to metastatic breast cancer and metastatic gastric
cancer (SB3, ABP 980 and CT-P6) as well as from metastatic breast
cancer to early breast cancer and metastatic gastric cancer (MYL-
1401O), based on the totality of evidence for biosimilarity.49–51,53
CLINICAL IMPLEMENTATION AND STRATEGIC
CONSIDERATIONS OF TRASTUZUMAB BIOSIMILARS
Switching between the reference product and biosimilar versions
of trastuzumab
Initiating treatment with an approved trastuzumab biosimilar is as
safe and effective as initiating treatment with the reference
product. However, questions have been raised about switching
between a reference product and its biosimilar or between
biosimilars of the same reference product.78 Although no issues
have been identiﬁed thus far with switching from a reference
product to its biosimilar,79 a concern is that switching could
potentially lead to increased immunogenicity, owing to the
subsequent exposure to potentially different sets of epitopes
owing to minor differences that might exist between the
reference product and the biosimilar. An increasing amount
of data from both phase 3 extension trials and real-world
studies evaluating the impact of switching are available for
biosimilars of various products, including inﬂiximab, etanercept
and adalimumab.79,80
In 2016, the European Society for Medical Oncology published a
position paper about biosimilars, indicating that the decision to
switch from the reference product to a biosimilar should be taken
by the physician.81 Furthermore, when switching, the patient
should be adequately informed and subsequently monitored,
allowing any adverse events to be traced to the relevant
product.81
Thus far, eight switching studies with anticancer mAb
biosimilars have been published.80 Seven of these studies were
conducted for rituximab biosimilars and one study has been
conducted for a trastuzumab biosimilar, ABP 980.80 Reported
results indicated that switching from the trastuzumab reference
product to ABP 980 following surgery was safe in patients with
early breast cancer (single switch, parallel arm, n= 171 in each
arm). The frequency and severity of adverse events did not
increase, no unexpected safety signals were noted and no
increased incidence of antidrug antibodies was reported.82
Trastuzumab is a relatively safe molecule with a low immuno-
genic potential for a mAb, limiting the risk of immunogenicity-
related adverse events. Although switching will normally occur
less frequently than for diseases requiring lifelong chronic
biological treatment, it still remains a possibility in practice, as
trastuzumab is administered for up to 1 year in early breast cancer
or until disease progression in metastatic breast cancer and
metastatic gastric cancer.10 Although no safety issues are to be
expected when switching, a cost/beneﬁt assessment could be of
interest to investigate the trade-off between the savings from
switching to a less expensive version and the costs from
implementing the switch, given the relatively short treatment
period.
Strategic considerations
The different companies developing trastuzumab biosimilars have
followed a variety of clinical development pathways, demonstrat-
ing the leeway given to biosimilar sponsors in determining the
clinical development strategy. There might be various reasons for
these different approaches, although we believe that there are
also important strategic considerations behind the decisions.
These considerations could apply to obtaining marketing author-
isation as quickly as possible or supporting the biosimilar in such a
way that it will receive higher product acceptance by stakeholders
and more support in the market. Running a trastuzumab
biosimilarity trial for metastatic breast cancer might beneﬁt from
faster patient accrual and possibly more-quickly attainable
clinically relevant endpoints compared with early breast cancer,
for example. Once licensed, early breast cancer will be an
extrapolated indication for these biosimilars (if decided so by
the EMA), but with potentially more reluctance among prescribers
to accept this. On the other hand, running a trial for early breast
cancer might be more difﬁcult in terms of attracting patients, but
clear proof in this indication might be more convincing and avoid
discussions by healthcare providers relating to extrapolated
indications once the product is on the market.
Potential implications of the market entry of trastuzumab
biosimilars
Roche has developed a subcutaneous formulation of trastuzumab,
which is reported to be more time efﬁcient (shorter patient chair
time and active healthcare professional time) than intravenous
infusion.83 When the total treatment costs of intravenous
trastuzumab and the subcutaneous version were compared in
the Netherlands in 2017, the subcutaneous preparation and
administration cost (including staff, material, premedication and
societal costs) was found to be 45% lower than the intravenous
administration. However, this cost accounts for a limited share
(<10%) of the total treatment cost (preparation and administration
cost plus the medicine price).84 The administration cost is thus
unlikely to outweigh the potential difference in medicine prices
(lower priced intravenous reference product due to competition or
lower priced intravenous biosimilar, versus patent protected,
more-expensive subcutaneous version).
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The arrival of biosimilars can potentially encourage manufac-
turers to invest in the development of new, innovative
products.7,85 Besides the subcutaneous formulation, Roche has
developed additional anti-HER2+ biopharmaceuticals, Perjeta®
and Kadcyla®.85,86 Perjeta® blocks receptor dimerisation by
targeting domain II of the extracellular component of HER2,
whereas Kadcyla® combines the actions of trastuzumab with an
anti-microtubule cytotoxic agent to facilitate intracellular delivery
of the drug.86,87 Both therapies are implemented in clinical
practice and are even more expensive than Herceptin®, with
treatment costs of ~75,000 Euros (18.5 months of treatment with
Perjeta®) and 57,000 euros (10 months of treatment with
Kadcyla®), based on Belgian list prices.13 Despite these innova-
tions, trastuzumab is likely to remain a cornerstone in the
treatment of HER2+ cancer86,88 and trastuzumab biosimilars can
have a signiﬁcant role in cost containment. Biosimilars have a
good value proposition, as their adoption allows to reduce the
healthcare budgetary burden and or potentially relocate funds to
new therapies.89 Biosimilar discounts can be as high as 60–90% of
the originator list price (depending on the product class and
country).90 Furthermore, the increased competition can drive
down prices not only for the reference product, but also for the
total therapy area segment, as previously identiﬁed by IMS Health
for other biosimilar classes.9,91
Beyond ﬁnancial beneﬁt, the use of biosimilars ultimately
provides patient beneﬁt, too. Biosimilar market entry has
previously been shown to improve patient access to biological
medicines (an increase in the number of treated patients and/or
more timely access to therapy).7 For example, in Sweden, the
launch of the biosimilar ﬁlgrastim led to the reassessment of
physician guidance on granulocyte colony-stimulating factor
prescribing, and promoted ﬁlgrastim to ﬁrst-line supportive care
in cancer. Subsequently, the uptake of ﬁlgrastim increased
ﬁvefold.7 As trastuzumab is not currently widely accessible around
the world owing to its high cost,14 the entry of more-affordable
versions of trastuzumab could open up treatment access.
Accordingly, this requires a sufﬁciently reduced price of the
trastuzumab biosimilars and/or the reference product itself.92 In a
physician survey in the USA and emerging markets by Lammers
and colleagues in 2014, nearly half of the oncologists questioned
reported that they would increase the use of HER2 targeted
therapy across treatment settings if a trastuzumab biosimilar was
available at a lower cost.14 The extent of the savings that can be
realised and the improvement in patient access to trastuzumab
will ultimately depend on the understanding and subsequent
conﬁdence of oncologists to prescribe trastuzumab biosimilars.
Physicians may expect products that are equally safe, qualitative
and effective as the reference product, and that have been
rigorously evaluated by regulatory authorities such as the EMA,
based on sound scientiﬁc principles.
The different routes taken in the clinical development of
trastuzumab biosimilars demonstrate that sponsors have some
ﬂexibility in setting up the clinical development of their product.
This should, however, not inﬂuence the conﬁdence in a
trastuzumab biosimilar once approved. Although a hierarchy
could be made based on the clinical assessment of biosimilars,60
this would not automatically allow the ranking of one trastuzumab
biosimilar above another, as biosimilarity is ﬁrst established
through analytical studies and further evaluated on the total
body of evidence, not solely on the design and results of the
clinical studies. Furthermore, this would not correspond with the
concept of biosimilarity. One biosimilar might have a more
extensive or sensitive clinical data package than another, but this
does not mean that this biosimilar should be considered more
similar to the reference product than the other, as all candidates
need to prove their overall similarity to the reference product.
However, a more elaborate and sensitive clinical package might
gain acceptance more convincingly by healthcare providers.
CONCLUSIONS
Several trastuzumab biosimilars are gradually entering the
European market. These biosimilars represent an important
opportunity for society in terms of cost savings and for patients
by opening up treatment access. Although some differences do
exist between the clinical development packages (in terms of trial
setting, clinical endpoint and patient population) of the trastuzu-
mab biosimilars, these differences need to be viewed in the
context of the totality of evidence approach for biosimilarity, in
which the clinical programme is a conﬁrmatory step. In order
to make informed decisions and to capture the potential of
biosimilars, it is essential to provide oncologists with adequate
information on the nature of the biosimilarity exercise and how
the clinical development of a biosimilar is tailored to meet the
licensing requirements.
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